isoxazoles has been researched along with Blood Clot in 22 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (27.27) | 18.2507 |
| 2000's | 12 (54.55) | 29.6817 |
| 2010's | 3 (13.64) | 24.3611 |
| 2020's | 1 (4.55) | 2.80 |
| Authors | Studies |
|---|---|
| Araújo, CDCB; Bonaccorso, C; Cabral, LM; da Silva, LCRP; de Almeida, GS; de Pádula, M; Ferorelli, S; Fortuna, CG; Miciaccia, M; Perrone, MG; Sathler, PC; Scilimati, A; Souza Domingos, TF; Vitale, P | 1 |
| Ali, MS; Bishop-Bailey, D; Bye, AP; Dombrowicz, D; Dorchies, E; Flora, GD; Gibbins, JM; Kriek, N; Molendi-Coste, O; Moraes, LA; Sage, T; Sasikumar, P; Staels, B; Unsworth, AJ; Vaiyapuri, S | 1 |
| Armstrong, PC; Emerson, M; Kirkby, NS; Mitchell, JA; Warner, TD; Zain, ZN | 1 |
| Davis, B; Farndale, RW; Jarvis, GE; Koch, A; Pugh, N; Sakariassen, KS | 1 |
| Billheimer, JT; He, B; Seiffert, D; Spitz, SM; Stern, AM | 1 |
| Alexander, RS; Bai, S; Clark, CG; Ellis, CD; Han, Q; He, MY; Knabb, RM; Lam, PY; Li, R; Luettgen, JM; Pinto, DJ; Quan, ML; Sun, JH; Teleha, CA; Wexler, RR; Wong, PC | 1 |
| Borgdorff, P; Paulus, WJ; Tangelder, GJ | 1 |
| Deray, G; Montalescot, G; Sibilia, J | 1 |
| Deray, G; Héloire, F; Valat, JP | 1 |
| Crain, EJ; Knabb, RM; Lam, PY; Quan, ML; Watson, CA; Wexler, RR; Wong, PC | 1 |
| Davis, CL; de Boer, IH; Jefferson, JA; Kendrick, EA; Kowalewska, J; Leca, N; Muczynski, KA; Pichler, R | 1 |
| Mannon, RB | 1 |
| Bozarth, J; Forsythe, M; Mousa, SA; Mu, DX; Wityak, J | 1 |
| Hussain, MA; Mousa, SA; Mu, DX | 1 |
| Alexander, RS; Ellis, CD; Knabb, RM; Lam, G; Liauw, AY; Quan, ML; Wexler, RR; Wong, PC; Wright, MR | 1 |
| Bostrom, LL; Carini, DJ; Ellis, CD; Harrison, K; Huang, PP; Knabb, RM; Liauw, AY; Pruitt, JR; Quan, ML; Thoolen, MJ; Wexler, RR; Wong, PC | 1 |
| Kapil, R; Mousa, SA; Mu, DX | 1 |
| Crain, EJ; Knabb, RM; Quan, ML; Watson, CA; Wexler, RR; Wong, PC | 1 |
| Bostrom, LL; Estrella, MJ; Knabb, RM; Pinto, DJ; Pruitt, JR; Wexler, RR; Wong, PC; Wright, MR | 1 |
| Christ, DD; Diamond, S; Gan, L; Mutlib, AE; Nemeth, G; Shockcor, J; Way, R | 1 |
| Abulencia, JP; Konstantopoulos, K; McCarty, OJ; Mousa, SA; Turner, NA | 1 |
2 review(s) available for isoxazoles and Blood Clot
| Article | Year |
|---|---|
[What do we know about the cardiovascular toxicity of the NSAIDs?].
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Case-Control Studies; Celecoxib; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Follow-Up Studies; Humans; Isoxazoles; Lactones; Meta-Analysis as Topic; Middle Aged; Naproxen; Pyrazoles; Randomized Controlled Trials as Topic; Risk Factors; Sulfonamides; Sulfones; Thrombosis; Time Factors | 2006 |
[Are there any differences in the cardiovascular tolerance between classical NSAIDs and coxibs?].
Topics: Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Case-Control Studies; Celecoxib; Cohort Studies; Cyclooxygenase 2 Inhibitors; Diclofenac; Edema; Heart Failure; Humans; Hypertension; Isoxazoles; Lactones; Meta-Analysis as Topic; Middle Aged; Odds Ratio; Placebos; Prospective Studies; Pyrazoles; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Assessment; Risk Factors; Sulfonamides; Sulfones; Thrombosis; Time Factors | 2006 |
20 other study(ies) available for isoxazoles and Blood Clot
| Article | Year |
|---|---|
An attempt to chemically state the cross-talk between monomers of COX homodimers by double/hybrid inhibitors mofezolac-spacer-mofezolac and mofezolac-spacer-arachidonic acid.
Topics: Algorithms; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arachidonic Acid; Blood Coagulation; Chlorocebus aethiops; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Erythrocytes; Humans; Isoxazoles; Models, Molecular; Protein Binding; Protein Multimerization; Structure-Activity Relationship; Thrombosis; Vero Cells | 2021 |
Farnesoid X Receptor and Its Ligands Inhibit the Function of Platelets.
Topics: Animals; Blood Platelets; Calcium Signaling; Chenodeoxycholic Acid; Cyclic GMP; Disease Models, Animal; Dose-Response Relationship, Drug; Fibrinogen; Genotype; Hemostasis; Humans; Isoxazoles; Ligands; Mice, Inbred C57BL; Mice, Knockout; Phenotype; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Receptors, Cytoplasmic and Nuclear; Thrombosis; Time Factors | 2016 |
Thrombosis is reduced by inhibition of COX-1, but unaffected by inhibition of COX-2, in an acute model of platelet activation in the mouse.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Animals; Aspirin; Collagen; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Diclofenac; Disease Models, Animal; Isoxazoles; Male; Membrane Proteins; Mice; Mice, Inbred BALB C; Thrombosis | 2011 |
The impact of factor Xa inhibition on axial dependent arterial thrombus formation triggered by a tissue factor rich surface.
Topics: Adolescent; Adult; Dose-Response Relationship, Drug; Factor Xa; Factor Xa Inhibitors; Humans; Isoxazoles; Male; Middle Aged; Perfusion; Pyrazoles; Surface Properties; Thromboplastin; Thrombosis; Young Adult | 2012 |
Effects of glycoprotein IIb/IIIa antagonists on platelet activation: development of a transfer method to mimic peak to trough receptor occupancy.
Topics: Alanine; Amidines; Benzodiazepines; Blood Platelets; Humans; In Vitro Techniques; Isoxazoles; Oximes; P-Selectin; Piperidines; Platelet Adhesiveness; Platelet Aggregation; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrrolidines; Thrombosis | 2002 |
Discovery of 1-(3'-aminobenzisoxazol-5'-yl)-3-trifluoromethyl-N-[2-fluoro-4- [(2'-dimethylaminomethyl)imidazol-1-yl]phenyl]-1H-pyrazole-5-carboxyamide hydrochloride (razaxaban), a highly potent, selective, and orally bioavailable factor Xa inhibitor.
Topics: Administration, Oral; Animals; Biological Availability; Blood Proteins; Caco-2 Cells; Crystallography, X-Ray; Dogs; Factor Xa Inhibitors; Fibrinolytic Agents; Humans; Imidazoles; Isoxazoles; Models, Molecular; Permeability; Protein Binding; Pyrazoles; Rabbits; Structure-Activity Relationship; Thrombosis | 2005 |
Cyclooxygenase-2 inhibitors enhance shear stress-induced platelet aggregation.
Topics: Animals; Aspirin; Clopidogrel; Coronary Artery Bypass; Coronary Stenosis; Cyclooxygenase Inhibitors; Isoxazoles; Platelet Aggregation; Platelet Aggregation Inhibitors; Rats; Risk Factors; Shear Strength; Thrombosis; Ticlopidine | 2006 |
Razaxaban, a direct factor Xa inhibitor, in combination with aspirin and/or clopidogrel improves low-dose antithrombotic activity without enhancing bleeding liability in rabbits.
Topics: Animals; Aspirin; Blood Coagulation; Clopidogrel; Disease Models, Animal; Drug Therapy, Combination; Factor Xa; Fibrinolytic Agents; Hemorrhage; Hemostasis; Isoxazoles; Male; Platelet Aggregation; Pyrazoles; Rabbits; Thrombosis; Ticlopidine | 2007 |
Higher levels of leflunomide are associated with hemolysis and are not superior to lower levels for BK virus clearance in renal transplant patients.
Topics: Adult; Aged; Antiviral Agents; BK Virus; Dose-Response Relationship, Drug; Female; Graft Rejection; Hemolysis; Humans; Immunosuppressive Agents; Isoxazoles; Kidney; Kidney Transplantation; Leflunomide; Male; Middle Aged; Polyomavirus Infections; Retrospective Studies; Thrombosis; Time Factors; Viral Load | 2008 |
Leflunomide therapy in kidney transplantation: ready for prime time?
Topics: Antiviral Agents; BK Virus; Dose-Response Relationship, Drug; Graft Rejection; Hemolysis; Humans; Immunosuppressive Agents; Isoxazoles; Kidney; Kidney Transplantation; Leflunomide; Polyomavirus Infections; Thrombosis; Time Factors; Viral Load | 2008 |
Intravenous and oral antiplatelet/antithrombotic efficacy and specificity of XR300, a novel nonpeptide platelet GPIIb/IIIa antagonist.
Topics: Administration, Oral; Amino Acids; Animals; Antithrombins; Carotid Arteries; Disease Models, Animal; Dogs; Female; Humans; Hydrolysis; Infusions, Intravenous; Isoxazoles; Kinetics; Male; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Thrombosis | 1998 |
Intranasal antiplatelet/antithrombotic efficacy of a novel platelet GPIIB/IIIA receptor antagonist DMP755.
Topics: Administration, Intranasal; Administration, Oral; Amino Acids; Animals; Biological Availability; Carotid Arteries; Dogs; Female; Femoral Artery; Fibrinolytic Agents; Injections, Intravenous; Isoxazoles; Male; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Thrombosis | 1998 |
Design and synthesis of isoxazoline derivatives as factor Xa inhibitors. 2.
Topics: Animals; Arteriovenous Shunt, Surgical; Binding Sites; Crystallography, X-Ray; Dogs; Factor Xa Inhibitors; Fibrinolytic Agents; Humans; Isoxazoles; Models, Molecular; Rabbits; Structure-Activity Relationship; Tetrazoles; Thrombin; Thrombosis; Trypsin; Trypsin Inhibitors | 1999 |
Design and synthesis of isoxazoline derivatives as factor Xa inhibitors. 1.
Topics: Acetates; Animals; Arteriovenous Shunt, Surgical; Binding Sites; Biphenyl Compounds; Factor Xa Inhibitors; Fibrinolytic Agents; Humans; Isoxazoles; Models, Molecular; Rabbits; Structure-Activity Relationship; Thrombosis | 1999 |
Intravenous and oral antithrombotic efficacy of the novel platelet GPIIb/IIIa antagonist roxifiban (DMP754) and its free acid form, XV459.
Topics: Administration, Oral; Amidines; Amino Acids; Animals; Bleeding Time; Disease Models, Animal; Dogs; Electroshock; Female; Femoral Artery; Humans; Injections, Intravenous; Isoxazoles; Male; Platelet Adhesiveness; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Thrombosis | 1999 |
Roxifiban. DMP 754, MK 0853, XJ 754.
Topics: Amidines; Animals; Dogs; Humans; In Vitro Techniques; Isoxazoles; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Thrombosis | 1999 |
Nonpeptide factor Xa inhibitors: I. Studies with SF303 and SK549, a new class of potent antithrombotics.
Topics: Animals; Anticoagulants; Arteriovenous Shunt, Surgical; Blood Coagulation; Dalteparin; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Fibrinolytic Agents; Heparin; Humans; In Vitro Techniques; Isoxazoles; Male; Naphthalenes; Platelet Aggregation; Propionates; Rabbits; Recombinant Proteins; Sulfonamides; Tetrazoles; Thrombosis | 2000 |
Isoxazolines and isoxazoles as factor Xa inhibitors.
Topics: Animals; Crystallography, X-Ray; Factor Xa Inhibitors; Isoxazoles; Models, Molecular; Rabbits; Serine Proteinase Inhibitors; Structure-Activity Relationship; Thrombosis | 2000 |
Mass spectrometric and NMR characterization of metabolites of roxifiban, a potent and selective antagonist of the platelet glycoprotein IIb/IIIa receptor.
Topics: Amidines; Amino Acids; Animals; Cardiovascular Agents; Chromatography, High Pressure Liquid; Dogs; Feces; Gas Chromatography-Mass Spectrometry; Humans; Isoxazoles; Liver; Magnetic Resonance Spectroscopy; Mass Spectrometry; Mice; Platelet Glycoprotein GPIIb-IIIa Complex; Rats; Thrombosis | 2000 |
Comparative efficacy between the glycoprotein IIb/IIIa antagonists roxifiban and orbofiban in inhibiting platelet responses in flow models of thrombosis.
Topics: Alanine; Amidines; Blood Platelets; Dose-Response Relationship, Drug; Fibrinolytic Agents; Humans; Isoxazoles; Models, Biological; Platelet Adhesiveness; Platelet Aggregation; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrrolidines; Thrombosis | 2002 |